Breaking News Instant updates and real-time market news.

AMGN

Amgen

$161.87

-2.42 (-1.47%)

, DD

Changed to DWDP

$69.14

1 (1.47%)

16:01
10/14/16
10/14
16:01
10/14/16
16:01

Amgen names former DuPont CEO Kullman to board

Amgen (AMGN) announced the appointment of Ellen J. Kullman to the Amgen board of directors, effective Oct. 14, 2016. Kullman will serve as a member of the Audit Committee and the Governance and Nominating Committee of the board. Following the appointment of Kullman, the board will comprise 14 directors, 13 of whom are independent. Kullman is the former president, chair and chief executive officer of DuPont (DD), where she served from January 2009 to October 2015.

AMGN

Amgen

$161.87

-2.42 (-1.47%)

DD

Changed to DWDP

$69.14

1 (1.47%)

  • 05

    Nov

  • 06

    Nov

  • 19

    Jul

AMGN Amgen
$161.87

-2.42 (-1.47%)

09/01/16
09/01/16
NO CHANGE

Amgen's sBLA for Blincyto approved by FDA
Amgen's supplemental Biologics License Application for Blincyto has been approved by the FDA to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. The approval is based on results from the Phase 1/2 '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of BLINCYTO in pediatric patients with relapsed or refractory B-cell precursor ALL. Blincyto was granted breakthrough therapy, priority review and orphan drug designations by FDA, and is now approved in the U.S. for the treatment of Ph- relapsed or refractory B-cell precursor ALL. In November 2015, BLINCYTO was granted conditional marketing authorization in the European Union for the treatment of adults with Ph- relapsed or refractory B-cell precursor ALL.
09/27/16
GSCO
09/27/16
NO CHANGE
Target $206
GSCO
Conviction Buy
Goldman surprised by Amgen's Kyprolis outcome in first-line multiple myeloma
Last night, Amgen announced Phase 3 Kypolis CLARION study did not meet the primary endpoint in first-line multiple myeloma. Goldman analyst Terence Flynn was surprised by this outcome given the prior positive superiority data for Kyprolis versus Velcade in the Phase III ENDEAVOR trial. Flynn sees risk to his Kyprolis $1B sales estimate in a first-line setting, but awaits for additional details from the call and further information regarding another ongoing Phase III trial. He expects Amgen shares to be weak on the news but said the company has additional drivers beyond Kyprolis including Repatha for high cholesterol and Erenumab for migraine with additional data expected in 2H 2016 and Q1 2017. Flynn remains Conviction Buy rated on Amgen and maintains his $206 price target.
09/27/16
PIPR
09/27/16
NO CHANGE
PIPR
Overweight
Amgen's Kyprolis in good shape despite trial miss, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Amgen's Kyprolis is still likely to be viewed as a "potent backbone, with the right drugs" after a Phase 3 study in front-line myeloma failed to reach its primary endpoint. The analyst believes the impact of the failed trial on Kyprolis use will be limited and he reiterates an Overweight rating on Amgen.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.
DD Changed to DWDP
$69.14

1 (1.47%)

10/03/16
SBSH
10/03/16
UPGRADE
SBSH
Buy
Dow Chemical upgraded to Buy from Neutral at Citi
Citi analyst P.J. Juvekar upgraded Dow Chemical (DOW) to Buy from Hold citing the opportunity presented by the proposed merger with DuPont (DD). The analyst also upgraded DuPont to Buy from Hold this morning.
10/03/16
SBSH
10/03/16
UPGRADE
SBSH
Buy
Citi upgrades Dow and DuPont, says DowDuPont could be 'stock to own' in 2017
As previously reported, Citi analyst P.J. Juvekar upgraded shares of both Dow Chemical (DOW) and DuPont (DD), each to Buy from Hold, citing their "massive" cost-cutting opportunity after their proposed merger goes through as well as the potential for upside to the companies' stated $3B synergy target. If their deal gets completed, the combined Dow-DuPont would "be the stock to own in 2017," said Juvekar, who raised the firm's price target on DuPont shares to $76 from $72 and increased the target for Dow shares to $59 from $55.
10/03/16
10/03/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dow Chemical (DOW) and DuPont (DD) were upgraded to Buy from Neutral at Citi with analyst P.J. Juvekar citing he opportunity presented by the proposed merger. 2. Freeport McMoRan (FCX), Barrick Gold (ABX), and Pan American Silver (PAAS) were upgraded to Buy from Hold at Deutsche Bank. 3. LogMeln (LOGM) upgraded to Overweight from Equal Weight at Barclays with analyst Raimo Lenschow saying the pending merger with Citrix's (CTXS) divested GoTo assets creates a "great new opportunity." 4. Halliburton (HAL) upgraded to Buy from Hold at Societe General. 5. Coty (COTY) upgraded to Buy from Neutral at BofA/Merrill with analyst Olivia Tong saying she believes Coty is at the beginning of a potential transformation with the pending closure of the P&G Beauty deal this week that could bring increased scale as well as a more targeted operational structure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/16
UBSW
10/10/16
UPGRADE
Target $62
UBSW
Buy
Dow Chemical upgraded to Buy from Neutral at UBS
UBS analyst John Roberts upgraded Dow Chemical (DOW) to Buy saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." The analyst sees $3B in potential cost savings and expects improving cash flow. Roberts raised his price target for the shares to $62 from $53.

TODAY'S FREE FLY STORIES

AMAT

Applied Materials

$47.15

-0.13 (-0.27%)

07:50
09/22/17
09/22
07:50
09/22/17
07:50
Conference/Events
Applied Materials to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

07:50
09/22/17
09/22
07:50
09/22/17
07:50
General news
Fedspeak returned from the blackout period »

Fedspeak returned from…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:49
09/22/17
09/22
07:49
09/22/17
07:49
Hot Stocks
Phillips 66 Partners to sell $750M of Series A preferred units »

Phillips 66 Partners LP…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Hot Stocks
Phillips 66 Partners announces $2.4B acquisition of interests from Phillips 66 »

Phillips 66 Partners…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$21.60

-0.25 (-1.14%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Recommendations
Versartis analyst commentary  »

Cantor still sees 55%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXEL

Exelixis

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Downgrade
Exelixis rating change  »

Exelixis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners »

Phillips 66 Partners to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$24.66

-1.13 (-4.38%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Technical Analysis
Technical View: U.S. Steel falls in early trading, analyst action »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

07:45
09/22/17
09/22
07:45
09/22/17
07:45
Recommendations
Zimmer Biomet analyst commentary  »

Value investors should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:45
09/22/17
09/22
07:45
09/22/17
07:45
General news
N.Y. FX Outlook »

N.Y. FX Outlook: The…

BABA

Alibaba

$177.39

-0.56 (-0.31%)

, TCEHY

Tencent

$44.15

-0.15 (-0.34%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Periodicals
Alibaba, Tencent look towards emerging markets in mobile-payments race, WSJ says »

Chinese companies Alibaba…

BABA

Alibaba

$177.39

-0.56 (-0.31%)

TCEHY

Tencent

$44.15

-0.15 (-0.34%)

AAPL

Apple

$153.39

-2.68 (-1.72%)

GOOG

Alphabet

$932.45

0.87 (0.09%)

GOOGL

Alphabet Class A

$947.55

0.01 (0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

SPR

Spirit AeroSystems

$78.90

0.76 (0.97%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Conference/Events
Spirit AeroSystems to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

AERI

Aerie Pharmaceuticals

$51.45

-1.95 (-3.65%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Recommendations
Aerie Pharmaceuticals analyst commentary  »

Aerie pullback on AdComm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Feb

CSCO

Cisco

$32.70

0.1 (0.31%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Conference/Events
Cisco management to meet with Deutsche Bank »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

EFX

Equifax

$98.25

2.25 (2.34%)

07:41
09/22/17
09/22
07:41
09/22/17
07:41
Technical Analysis
Technical View: Equifax trades higher, analyst action »

Shares are back well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AA

Alcoa

$46.25

-1.25 (-2.63%)

07:41
09/22/17
09/22
07:41
09/22/17
07:41
Downgrade
Alcoa rating change  »

Alcoa downgraded to Hold,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMX

CarMax

$68.84

0.17 (0.25%)

07:40
09/22/17
09/22
07:40
09/22/17
07:40
Earnings
CarMax reports Q2 EPS 98c, consensus 95c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

SYK

Stryker

$140.67

-2.04 (-1.43%)

, ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

07:40
09/22/17
09/22
07:40
09/22/17
07:40
Recommendations
Stryker, Zimmer Biomet analyst commentary  »

Growth investors should…

SYK

Stryker

$140.67

-2.04 (-1.43%)

ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

SAVE

Spirit Airlines

$34.01

1.31 (4.01%)

07:39
09/22/17
09/22
07:39
09/22/17
07:39
Conference/Events
Spirit Airlines to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

IBM

IBM

$145.26

-0.62 (-0.43%)

, WBA

Walgreens Boots Alliance

$78.20

-0.64 (-0.81%)

07:39
09/22/17
09/22
07:39
09/22/17
07:39
Hot Stocks
IBM announces new agreement with Walgreens to deploy IBM retail analytics »

IBM (IBM) announced a new…

IBM

IBM

$145.26

-0.62 (-0.43%)

WBA

Walgreens Boots Alliance

$78.20

-0.64 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 23

    Sep

  • 22

    Oct

  • 25

    Oct

  • 15

    Nov

07:38
09/22/17
09/22
07:38
09/22/17
07:38
Conference/Events
Federal Reserve Bank of Dallas President participates in a conference »

Dallas Federal Reserve…

07:37
09/22/17
09/22
07:37
09/22/17
07:37
Conference/Events
Federal Reserve Bank of Kansas City President to speak at conference »

Kansas City Federal…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.